ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1938 • ACR Convergence 2021

    A Phenome-Wide Association Study of Genes Associated with COVID-19 Severity Reveals Shared Genetics with Rheumatic Conditions

    Anurag Verma1, Noah Tsao1, Lauren Thomann2, Yuk-Lam Ho2, Rotonya Carr1, Dana crawford3, Jimmy efird4, Jennifer Huffman2, Adriana Hung5, Kerry Ivey2, Sudha Iyengar3, Michael Levin6, Shiuh-Wen luoh7, Julie Lynch8, Pradeep Natarajan9, Saiju Pyarajan10, alexander Bick11, Lauren Costa2, Giulio Genovese12, Richard Hauger13, Ravi madduri14, Gita Pathak15, Renato polimanti15, Benjamin Voight1, Marijana Vujkovic1, Maryam Zekavat15, Hongyu Zhao15, Marylyn Ritchie1, Kyong-Mi Chang16, Kelly Cho2, Juan casas2, Phil Tsao17, J. Michael Gaziano2, Christopher ODonnell2, Scott Damrauer1 and Katherine Liao18, 1University of Pennsylvania, Philadelphia, PA, 2VA Boston Healthcare System, Boston, MA, 3Case Western Reserve University, Cleveland, OH, 4DVAHCS, Durham, 5Vanderbilt University Medical Center, Nashville, TN, 6University of Pennsylvania, Philadelphia, 7Oregon Health & Science University, Portland, 8VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, 9Massachusetts General Hospital, Boston, MA, 10Partners, Boston, 11Vanderbilt University, Nashville, TN, 12Harvard Medical School, Boston, MA, 13University of California San Diego, San Diego, CA, 14Argon National Lab, Chicago, IL, 15Yale University, New Haven, CT, 16VA Philadelphia, Philadelphia, PA, 17VA Palo Alto, Palo Alto, CA, 18Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Severe coronavirus disease 2019 (COVID-19) is associated with a broad range of clinical conditions. International efforts have led to the identification of risk alleles…
  • Abstract Number: 1920 • ACR Convergence 2021

    Association of C-reactive Protein and Non-Steroidal Anti-inflammatory Drugs with Cardiovascular Events in Patients with Psoriatic Arthritis: A Time-dependent Cox Regression Analysis

    Ho Man Lam1, Ho So2, Isaac Cheng1, Edmund Li1, Priscilla Wong3, Tena Li1, Alex Lee1 and Lai-Shan Tam4, 1The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2CUHK, Hong Kong, China, 3Prince of Wales Hospital, Hong Kong, Hong Kong, 4Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic)

    Background/Purpose: Psoriatic arthritis (PsA) is associated with accelerated atherosclerosis due to underlying inflammation. Whether inflammatory burden and drugs used to suppress inflammation over time are…
  • Abstract Number: 1899 • ACR Convergence 2021

    Mortality in Patients with Sub-Optimally Treated Gout in the Veteran’s Health Administration: A National Retrospective Cohort Study

    Lindsay Helget1, Bryant England1, Punyasha Roul1, Harlan Sayles1, Alison Petro1, Tuhina Neogi2 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2Boston University School of Medicine, Boston, MA

    Background/Purpose: Patients with gout have an increased risk of mortality. Current ACR guidelines for the treatment of gout recommend a treat-to-target approach with titration of…
  • Abstract Number: PP03 • ACR Convergence 2021

    Navigating Maintenance of a Rare Autoimmune Rheumatic Disease in the Context of the COVID-19 Pandemic

    Ida Hakkarinen, Greenbelt, MD

    Background/Purpose: On March 13th, 2020, the President of the United States issued a proclamation declaring that the outbreak of coronavirus disease 2019 (COVID-19) was a…
  • Abstract Number: PP01 • ACR Convergence 2021

    Unicycling for a Cure: My UNIque Physical Activity Intervention for Rheumatoid Arthritis During the COVID19 Pandemic

    Dana Guglielmo, San Diego, CA

    Background/Purpose: I was diagnosed with rheumatoid arthritis at age 17. In my 20s, I joined Racing For A Cure of the Arthritis National Research Foundation,…
  • Abstract Number: PP06 • ACR Convergence 2021

    Collaborative Advocacy Helps Me and Other Patients With Relapsing Polychondritis (“RP”’) /  My life improved by helping the RP Foundation and Race for RP facilitate awareness, education, and research to improve the quality of life for patients with RP and advance a cure for this disease.

    Michael Linn1 and Dan Smith2, 1Relapsing Polychondritis Foundation, New York, NY, 2Relapsing Polychondritis Foundation, Canton, MI

    Background/Purpose: In March 2020, I was diagnosed as having relapsing polychondritis ("RP"), an understudied, underdiagnosed, and undertreated debilitating autoimmune disease that can be fatal if…
  • Abstract Number: PP05 • ACR Convergence 2021

    Fighting Health-Related Misinformation Using Social Media / How Creating an Online Group for Patients with Relapsing Polychondritis — and Moderating It with Health Professionals — Helps Spread Reliable and Empowering Information

    Michael Linn1, Spenser Mestel2 and Susie Ratledge3, 1Relapsing Polychondritis Foundation, New York, NY, 2New York, NY, 3Relapsing Polychondritis: Secular Science and Support group, Chattanooga, TN

    Background/Purpose: Before I became ill in 2017, I was a registered nurse with a degree in health science who'd often educate patients about how they…
  • Abstract Number: PP08 • ACR Convergence 2021

    Should I Get the COVID-19 Vaccine With My RA? Using Evidence-Based Resources for Decision-Making

    Aberdeen Allen, Colgate Palmolive, Parlin, NJ

    Background/Purpose: Patients with autoimmune rheumatic diseases have concerns about getting the COVID-19 vaccine. As vaccines began to receive emergency use authorization, individuals with conditions like…
  • Abstract Number: PP09 • ACR Convergence 2021

    Family Planning while Living with Rheumatoid Arthritis

    Shannan O'Hara-Levi, Monroe, NY

    Background/Purpose: Over the course of my 30+ years living with Polyarticular Juvenile Rheumatoid Arthritis, I have never had long term success on any one biologic treatment,…
  • Abstract Number: 1946 • ACR Convergence 2021

    Therapeutic Drug Monitoring Compared to Standard Infliximab Therapy in Patients with Immune-mediated Inflammatory Diseases: A Randomized Controlled Trial

    Silje Watterdal Syversen1, Guro Goll1, Kristin Jørgensen2, Marthe Brun1, Øystein Sandanger3, Kristin Hammersbøen2, Joseph Sexton1, Inge Olsen3, Johanna Gehin4, David Warren3, Rolf Anton Klaasen3, Trude Bruun5, Maud Kristine Ljoså6, Anne Haugen7, Rune Njålla8, Brigitte Michelsen9, Camilla Zettel10, Yngvill Bragenes11, Svanaug Skorpe12, Eldri Strand13, Pawel Mielnik14, Cato Mørk15, Tore Kvien1, Jørgen Jahnsen2, Nils Bolstad16 and Espen Haavardsholm1, 1Diakonhjemmet Hospital, Oslo, Norway, 2Akershus University Hospital, Lørenskog, Norway, 3Oslo University Hospital, Oslo, Norway, 4Oslo University Hospital, Lillehammer, Nepal, 5The University Hospital of North Norway, Tromsø, Norway, 6Dept. of Rheumatology, Ålesund Hospital, Ålesund, Norway, 7Østfold Hospital Trust, Moss, Norway, 8Nordland Hospital Trust, Bodø, Bodø, Norway, 9Hospital of Southern Norway Trust, Kristiansand, Norway, 10Betanien Hospital, Skien, Norway, 11Vestre Viken Hospital Trust, Drammen, Norway, 12Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, 13Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 14Førde Hospital Trust, Førde, Norway, 15Akershus Dermatology Center, Lørenskog, Norway, 16Oslo University Hospital, Radiumhospitalet, Oslo, Norway

    Background/Purpose: Proactive therapeutic drug monitoring (TDM), a treatment strategy based on scheduled assessments of serum drug levels, has been proposed to optimize efficacy and safety…
  • Abstract Number: PP11 • ACR Convergence 2021

    “Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases

    Trishtha Peters1 and Natasha Trehan2, 1University of Ontario, Toronto, ON, Canada, 2University of Ottawa, Toronto, ON, Canada

    Background/Purpose: Trish Peters was diagnosed with JIA at 11. She has been on Methotrexate to lessen disease activity for her knees and hands. She does…
  • Abstract Number: PP13 • ACR Convergence 2021

    CreakyKitchen: How the Online Cooking Show I Started is Building Community and Encouraging Better Food Choices for Me and Others Living with Rheumatic and Chronic Disease

    Chantelle Marcial, Boston, MA

    Background/Purpose: At 19, I was mis-diagnosed with Lupus as it was a common condition in my family. My treatment at that time was mainly DMARDs,…
  • Abstract Number: 1944 • ACR Convergence 2021

    Sustained Remission/Low Disease Activity Is Feasible in the Long Term in Patients with Psoriatic Arthritis Treated with IL-23/12 Inhibition with Ustekinumab (STELARA®) and Tumor Necrosis Factor Inhibitors in a Real-World, Multicenter Study

    Josef Smolen1, Paul Bergmans2, Kurt de Vlam3, Elisa Gremese4, Beatriz Joven-Ibáñez5, Tatiana Korotaeva6, Wim Noël7, Michael Nurmohamed8, Petros Sfikakis9, Stefan Siebert10, Elke Theander11 and Laure Gossec12, 1Medical University of Vienna, Vienna, Austria, 2Janssen-Cilag BV, Breda, Netherlands, 3University Hospitals Leuven, Leuven, Belgium, 4Fondazione Policlinico A Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, 5University Hospital 12 de Octubre, Madrid, Spain, 6VA Nasonova Research Institute of Rheumatology, Moscow, Russia, 7Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, 8Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, 9National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, 10University of Glasgow, Glasgow, United Kingdom, 11Janssen Cilag, Lund, Sweden, 12Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France

    Background/Purpose: Among treatment options for PsA, IL-23/12 inhibition with ustekinumab (UST) was the first new biologic after TNF inhibitors (TNFi). Few data compare long-term effectiveness…
  • Abstract Number: 1943 • ACR Convergence 2021

    Post-inflammatory and Degenerative Changes in Patients with Psoriatic Arthritis and Axial Manifestations: Post-hoc Analysis from a Double-blind, Randomized, Phase 3b Trial

    Xenofon Baraliakos1, Effie Pournara2, Laura Coates3, Victoria Navarro-Compán4, Roisin White5, Barbara Schulz2 and Robert Landewé6, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2Novartis Pharma AG, Basel, Switzerland, 3Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 4Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, 5Novartis Ireland Limited, Dublin, Ireland, 6Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands

    Background/Purpose: Axial psoriatic arthritis (PsA) is the only one of the PsA manifestations, still not clearly defined, with no currently available universally acceptable clinical and…
  • Abstract Number: 1894 • ACR Convergence 2021

    Natural Language Processing Tool for Extraction of Patient-Reported Outcomes from a National Multi-Electronic Health Records Registry

    Marie Humbert-Droz1, Zara Izadi2, Gabriela Schmajuk2, Milena Gianfrancesco2, Jinoos Yazdany2 and Suzanne Tamang3, 1Stanford University, Stanford, 2University of California San Francisco, San Francisco, CA, 3Stanford Center for Population Health Sciences, Redwood City, CA

    Background/Purpose: Patient reported outcomes (PROs) are increasingly used to track disease activity and facilitate shared decision making in patients with RA. Assessments of disease activity…
  • « Previous Page
  • 1
  • …
  • 629
  • 630
  • 631
  • 632
  • 633
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology